Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT

[1]  Annette Kopp-Schneider,et al.  Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[3]  K. Flaherty,et al.  Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. , 2017, Cancer research.

[4]  H. Hendel,et al.  Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy , 2017, Diagnostics.

[5]  Sanjiv S Gambhir,et al.  Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging , 2017, The Journal of Nuclear Medicine.

[6]  Steven P Rowe,et al.  Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma , 2017, The Journal of Nuclear Medicine.

[7]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[8]  F. Hodi,et al.  Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma , 2016, Journal of Immunotherapy for Cancer.

[9]  I. Weissman,et al.  Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging , 2015, Proceedings of the National Academy of Sciences.

[10]  F. Hodi,et al.  Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab , 2015, Cancer Immunology Research.

[11]  D. Hose,et al.  18F-FDG Dynamic PET/CT in Patients with Multiple Myeloma: Patterns of Tracer Uptake and Correlation With Bone Marrow Plasma Cell Infiltration Rate , 2015, Clinical nuclear medicine.

[12]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[13]  M. Muzi,et al.  Applications of PET imaging with the proliferation marker [18F]-FLT. , 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[14]  G. Paganelli,et al.  Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  R. Tavaré,et al.  Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo , 2014, Proceedings of the National Academy of Sciences.

[16]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[17]  J. Wolchok,et al.  Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma: How Different are these From Conventional Treatment Responses? , 2012, American journal of clinical oncology.

[18]  Leyun Pan,et al.  Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients , 2012, Cancer imaging : the official publication of the International Cancer Imaging Society.

[19]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[20]  A. Pavlick,et al.  A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma , 2011, Investigational New Drugs.

[21]  Yan Xing,et al.  Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. , 2011, Journal of the National Cancer Institute.

[22]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[23]  A. Ribas,et al.  Imaging of CTLA4 Blockade–Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab , 2010, Journal of Nuclear Medicine.

[24]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[25]  Michael Dougan,et al.  Immune therapy for cancer. , 2009, Annual review of immunology.

[26]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[27]  R. Dummer,et al.  Small bowel invagination caused by intestinal melanoma metastasis: unsuspected diagnosis by FDG-PET/CT imaging. , 2007, Clinical nuclear medicine.

[28]  Paul Garside,et al.  Reversal of the TCR Stop Signal by CTLA-4 , 2006, Science.

[29]  A. Alavi,et al.  Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  S. Swetter,et al.  Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients , 2002, Annals of Surgical Oncology.

[31]  O. Hoekstra,et al.  Systematic review of the diagnostic accuracy of 18F‐fluorodeoxyglucose positron emission tomography in melanoma patients , 2001, Cancer.

[32]  L. Friberg,et al.  Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma , 2000, European Journal of Nuclear Medicine.

[33]  T. Psaras,et al.  Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis. , 1999, Nuclear medicine communications.

[34]  W. Holder,et al.  Effectiveness of positron emission tomography for the detection of melanoma metastases. , 1998, Annals of surgery.

[35]  C Burger,et al.  Requirements and implementation of a flexible kinetic modeling tool. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  A. Osmont,et al.  Determination of 18F-fluoro-2-deoxy-d-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography , 1993, Journal of Neuroscience Methods.

[37]  T. Momose,et al.  Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  F. Denizot,et al.  A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.

[40]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[41]  B. Gückel,et al.  18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  A. Ribas,et al.  An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. , 2016, Cancer research.

[43]  A. Dimitrakopoulou-Strauss,et al.  Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  Liselotte Højgaard,et al.  Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. , 2013, American journal of nuclear medicine and molecular imaging.

[45]  C Burger,et al.  A JAVA environment for medical image data analysis: initial application for brain PET quantitation. , 1998, Medical informatics = Medecine et informatique.

[46]  Louis Sokoloff,et al.  Basic Principles Underlying Radioisotopic Methods for Assay of Biochemical Processes in Vivo , 1983 .